Poxel (STU:7PO) Tariff Resilience Score: 0/10 (As of Jul. 13, 2026)


STU:7PO Poxel SA STU:7PO
37 GF Score
Price €0.19
GF Value €1.08
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Poxel Tariff Resilience Score?

Poxel has the Tariff Resilience Score of 0, which implies that the company might have .

Poxel has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Poxel might have .

Poxel  (STU:7PO) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Poxel Tariff Resilience Score Related Terms

STU:7PO
37GF Score
Poxel SA STU:7PO
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Poxel (STU:7PO) Overvalued in 2026?

Based on GuruFocus' analysis, Poxel stock appears to be undervalued. The current stock price of €0.19 is trading 82.1% below its estimated GF Value™ of €1.08. GuruFocus considers Poxel to be Possible Value Trap.

Key valuation signals for STU:7PO:

  • Tariff Resilience Score: 0
  • GF Value™: €1.08 vs. price of €0.19 (82.1% below fair value)
  • GF Score™: 37/100 with 6 warning signs

No single metric tells the full story. See the STU:7PO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Poxel Business Description

Address 259/261 Avenue Jean Jaures, Immeuble le Sunway, Lyon, FRA, 69007
Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.
37GF Score

Get the complete analysis for STU:7PO

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.19
Price
€1.08
GF Value